KAI Pharmaceuticals Acquired By Amgen For $315M

South San Francisco-based KAI Pharmaceuticals, a biopharmaceuticals firm development treatment of secondary hyperparathroidism in patients with chronic kidney disease on dialysis, has been acquired by Amgen, the firms said today. Amgen said it would pay $315M in cash for KAI Pharmaceuticals, which was venture backed by InterWest Partners, Skyline Ventures, Intersouth Partners, Aberdare Ventures, Investor Growth Capital, Kearny Venture Partners, Lumira Capital and Delphi Ventures.